Document Detail

Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients.
MedLine Citation:
PMID:  10994664     Owner:  NLM     Status:  MEDLINE    
Most studies of prostate cancer have shown that strontium-89 chloride (89Sr) is effective in the palliation of metastatic bone pain, refractory to conventional analgesia. The aim of this study was to evaluate the usefulness of 89Sr for bone pain palliation in breast cancer patients. Forty women were treated with 148 MBq of 89Sr. Six patients were retreated, receiving two or more doses. The Karnofsky performance status was assessed and pain and analgesia were scored on scales of 9 and 5 points, respectively. The efficacy of 89Sr was evaluated at 3 months of treatment. The response was good in 60% of the patients and partial in 32%; there was no response in the remaining 8% (pre-treatment Karnofsky < or = 60). The duration of the response was 120+/-143 days. In the patients retreated, the response was good in 83% and partial in 17%, without significant differences compared with the first dose, but the pre-treatment Karnofsky and the duration of the efficacy were lower (P < 0.05). A transient and slight decrease of leukocyte and platelet counts after the first month of treatment with 59Sr was observed. In conclusion, breast cancer patients with metastatic bone pain can benefit from therapy with 89Sr. If necessary, the treatment may be repeated safely and with the same efficacy as is achieved after the first dose. A low functional performance status could be a cause of the lower effectiveness of 89Sr.
D Fuster; D Herranz; S Vidal-Sicart; M Muñoz; C Conill; J J Mateos; F Martín; F Pons
Related Documents :
23125004 - Draft working title: trajectories of psychological distress after colorectal cancer.
23084254 - The effects of a six-week supervised multimodal exercise intervention during chemothera...
23846934 - Highlights on novel imaging methods of pancreatic cancer.
24237744 - Visual screening for oral cancer may reduce oral cancer mortality in high-risk adult po...
12630564 - Toll-like receptor signaling in anti-cancer immunity.
21980014 - Survivors at higher risk for adverse late outcomes due to psychosocial and behavioral r...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Nuclear medicine communications     Volume:  21     ISSN:  0143-3636     ISO Abbreviation:  Nucl Med Commun     Publication Date:  2000 Jul 
Date Detail:
Created Date:  2001-02-02     Completed Date:  2001-02-02     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8201017     Medline TA:  Nucl Med Commun     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  623-6     Citation Subset:  IM    
Department of Nuclear Medicine, Hospital Clínic de Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Neoplasms / complications*,  secondary*
Breast Neoplasms / pathology*
Leukocyte Count
Middle Aged
Pain Measurement
Pain, Intractable / radiotherapy*
Strontium Radioisotopes / adverse effects,  diagnostic use
Reg. No./Substance:
0/Strontium Radioisotopes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Association of prostate-specific antigen levels and patterns of benign and malignant uptake detected...
Next Document:  Monitoring the effect of anticoagulants on left atrial thrombi in patients with rheumatic heart dise...